focus -WSS

focus

author：entertainment 2025-09-06 01:58:57 - browse：5646

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： New documents shed light on MD Anderson Cancer Institute feud

focus

knowledge

WSS

Long Covid needs a new name — and a new frame

IRA could hurt research into orphan drugs for rare diseases

Food makers to regulators: Ultra

Obesity drugs seen as possible treatment for liver disease MASH

Generate Biomedicines machine learning biotech raises $273M

New Covid vaccine is recommended for everyone 6 months or older

Wikipedia

focus

hotspot

In age of alternative facts, a scholarly course on calling out crap

A new nitrogen execution bill also undermines medical licensing

New air purifier tech could be key to improving indoor air quality

New Covid vaccine is recommended for everyone 6 months or older

Activists slam private health insurers over coverage restrictions

PBM reform efforts get punted in Congress

After affirmative action ruling, medical educators look to 'holistic review'

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Cancer drug shortages should be causing more outrage

How housing is health care on Long Island

knowledge

FDA panel endorses Alnylam’s heart drug — after picking it apart

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

With competition flaring, obesity drug hits goal in liver disease study

White House touts steps to stem shortages of cancer treatments

Generate Biomedicines machine learning biotech raises $273M

leisure time

focus

knowledge

explore